European Metabolic Disorder Therapeutics Market Size, Share, Analysis, Industry Report and Forecast – 2020-2026

By | November 16, 2020

European metabolic disorder therapeutics market is estimated to grow at a CAGR of 7.4% during the forecast period. Rising prevalence of metabolic disorders have been reported in the region, which is accelerating the growth of the market. According to the International Diabetes Federation (IDF), an estimated 59 million adults (20-79 years) were suffering from diabetes in the Europe Region. Europe has the largest number of adolescents and children (0-19 years) have type 1 diabetes, which is 296,500. Diabetes is a form of metabolic diseases that disrupt normal metabolism. Diabetic medications that are used for the treatment of the condition include Metformin (Glucophage, Glumetza, others), Thiazolidinediones (rosiglitazone (Avandia) and pioglitazone (Actos)), and others.

Please read the originial post here: https://www.omrglobal.com/industry-reports/european-metabolic-disorder-therapeutics-market